IQVIA Biotech’s Post

Historically, clinical trial technologies have been embraced more by larger organizations with ample resources and experience. But our latest survey of small biopharma, biotech and CRO organizations revealed that this trend is shifting. 📌 Of the 150 respondents, nearly all said at least half of their ongoing studies incorporate multiple trial technologies. How are these organizations using clinical trial technology to their advantage? What’s standing in the way of adoption? How confident are they that technology can keep up with evolving trial complexities? Get answers to these questions and many more in our latest survey report with BioPharma Dive: https://bit.ly/4esIiiX #Biotech #CRO #DataQuality #RealWorldData #ClinicalDataManagement

🔔 Last Call! 🔔 The BioBridges Conference 2024 wraps up today, but there's still a golden opportunity awaiting you! Our Director of Business Development, Mo H. and Director of Pharmacokinetics, Sunny Le are present and eager to connect with you. If you're at the conference or in the vicinity, don't miss this chance to discuss potential clinical collaborations and industry insights! BioPharma Services Inc. specializes in #Phase1 clinical trials, bioavailability, bioequivalence, First-in-Human and Human Abuse Potential Studies (#HAP). Let our world renowned Pharmacokinetics team execute your next clinical trial with confidence. . . . #clinicalresearch #clinicalstudies #clinicaltrials #cro #clinicaltrials #Biopharma #drugdevelopment #phase1 #biobridges #biobridges2024 #prauge

In the latest Health Innovation Roundup, sponsored by Health Cities: - Misericordia Community Hospital is the first place in Alberta to offer Acessa - Plus news from PulseMedica, GlycoNet, Pacylex Pharmaceuticals, Inc., RJH Biosciences - Inspired Design, Effective Transfection, Alberta Machine Intelligence Institute (Amii), Bio-Stream Diagnostics Inc., Action Lab, and more https://lnkd.in/gAt-gZwm #yeghealth #yeginnovation

Uncover essential insights into 2024 Biopharma funding trends with our brand-new report! 🔗https://ter.li/ps6d1 Despite funding challenges, 2024 has seen a shift in financing dynamics, with 25% of rounds surpassing $100m, up from 16% in 2023. The average round size climbed to $63.1m across 133 rounds, compared to $56.4m over 270 rounds last year. Key deals include J&J acquiring bispecifics for atopic dermatitis from Proteologix and Numab, and Vertex purchasing Alpine Immune Sciences for its lead asset targeting IgA nephropathy. Download your free copy to delve deeper into the data📊 #Biotech #Pharma #DrugDevelopment #FundingTrends

✨BioPharma Services Just Published a New Blog ― Start your year off right by learning more about our Medical Director and Principal Investigator, Dr. Janice Faulknor. In our latest blog, discover how Dr. Faulknor's leadership, expertise, and dedication drive innovation and success in early-phase clinical trials. 🔗 Read here: https://hubs.li/Q031gf0K0 BioPharma Services Inc. specializes in #Phase1 clinical trials, bioavailability, bioequivalence, First-in-Human and Human Abuse Potential Studies (#HAP). Let our world-renowned #Pharmacokinetics team execute your next clinical trial with confidence. . . . #clinicalresearch #clinicalstudies #clinicaltrials #bioanalsysis #cro #clinicaltrials #Biopharma #drugdevelopment #biotech #blog #pharmaceuticalindustry

World leaders at #UNGA79 on Wednesday pledged to reduce the estimated 4.95 million human deaths from antimicrobial resistance (#AMR) annually by 10% by 2030, recognizing “the important role played by the private sector.” Our investor’s guide to #AMR, published in collaboration with Access to Medicine Foundation and the FAIRR Initiative, shows how investors can view investments through an “#AMR lens,” which includes: - Understanding the global costs of #AMR - Supporting R&D in pharmaceuticals and biotech - Encouraging responsible practices in portfolio companies - Engaging in initiatives like Investor Action on #AMR Get the guide: https://lnkd.in/g4MgN8wc

Arrakis Founder and CSO Jennifer Petter presents the first data for our lead drug program using our proprietary platform to develop RNA-targeted small molecule (rSMs) medicines today at the #CellSymposia. #ExpeditionRNA    https://lnkd.in/gGM3HkEe

Ready to take your clinical trials for a spin? 🚴♀️💨 SimpleTrials is your all-terrain vehicle for navigating any research challenge. Shift gears and ride towards your goals with our intuitive CTMS! Learn more at https://buff.ly/3KsQaDT #ClinicalTrials #SimpleTrials #ClinicalEfficiency #CRO #biotech #pharma #ClinicalOperations

🚀 Biotech Growth in Clinical R&D: Leveraging CRO Partnerships for Success. The biotech industry is reshaping the landscape of clinical research, with a focus on groundbreaking therapies and rapid advancements in R&D. But with limited resources and the complexity of today’s trials, many biotechs are turning to strategic partnerships with CROs to help bridge the gap. Our latest blog explores: 🌐 The biotech R&D boom and market dynamics, 💼 Top challenges biotechs face for 2025, from data access to rising costs, 🤝 How CRO partnerships can offer essential expertise and drive innovation Read more here: https://lnkd.in/enrUXxuc #Biotech #ClinicalResearch #CRO #Pharma #Innovation #PrecisionMedicine #R&D

📺 Via Investor Stream: Tryptamine Therapeutics Limited Managing Director Jason Carroll joins Alex Paull of Investor Stream following a busy finish to 2024, and to preview the Company's key milestones for 2025. High on the agenda was advancing the Company's clinical development pathway for its lead drug candidate, TRP-8803, and Jason delves into the success of Phase 1b trials, the planning for Phase 2 and the pipeline of news flow projected for the first half of the year. Watch 👇 https://lnkd.in/dzDXdaJ2 #biotech #psychedelics #TYP #ASX #health #ASXnews #ASXinterview